<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p13" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_13{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_13{left:341px;bottom:30px;}
#t3_13{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_13{left:377px;bottom:30px;}
#t5_13{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_13{left:540px;bottom:30px;}
#t7_13{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_13{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_13{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_13{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_13{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_13{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_13{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_13{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_13{left:1130px;bottom:47px;letter-spacing:0.27px;}
#tg_13{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_13{left:36px;bottom:249px;}
#ti_13{left:46px;bottom:243px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_13{left:377px;bottom:243px;letter-spacing:0.12px;}
#tk_13{left:407px;bottom:243px;letter-spacing:0.13px;}
#tl_13{left:481px;bottom:243px;}
#tm_13{left:36px;bottom:232px;}
#tn_13{left:46px;bottom:226px;letter-spacing:0.1px;word-spacing:-0.02px;}
#to_13{left:45px;bottom:209px;letter-spacing:0.13px;}
#tp_13{left:36px;bottom:198px;}
#tq_13{left:46px;bottom:192px;letter-spacing:0.12px;word-spacing:0.01px;}
#tr_13{left:36px;bottom:182px;}
#ts_13{left:46px;bottom:176px;letter-spacing:0.12px;word-spacing:-0.04px;}
#tt_13{left:45px;bottom:159px;letter-spacing:0.11px;word-spacing:-0.03px;}
#tu_13{left:45px;bottom:142px;letter-spacing:0.13px;}
#tv_13{left:36px;bottom:131px;}
#tw_13{left:46px;bottom:125px;letter-spacing:0.12px;}
#tx_13{left:45px;bottom:108px;letter-spacing:0.12px;}
#ty_13{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#tz_13{left:765px;bottom:786px;}
#t10_13{left:43px;bottom:748px;letter-spacing:-0.1px;}
#t11_13{left:43px;bottom:729px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t12_13{left:46px;bottom:711px;letter-spacing:-0.1px;}
#t13_13{left:54px;bottom:693px;}
#t14_13{left:71px;bottom:693px;letter-spacing:-0.09px;}
#t15_13{left:70px;bottom:674px;letter-spacing:-0.09px;}
#t16_13{left:71px;bottom:656px;}
#t17_13{left:84px;bottom:656px;letter-spacing:-0.09px;}
#t18_13{left:91px;bottom:638px;letter-spacing:-0.09px;word-spacing:-0.02px;}
#t19_13{left:771px;bottom:645px;}
#t1a_13{left:91px;bottom:619px;letter-spacing:-0.16px;word-spacing:0.01px;}
#t1b_13{left:112px;bottom:601px;}
#t1c_13{left:125px;bottom:601px;letter-spacing:-0.09px;}
#t1d_13{left:112px;bottom:583px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1e_13{left:91px;bottom:564px;letter-spacing:-0.09px;word-spacing:-0.03px;}
#t1f_13{left:54px;bottom:546px;}
#t1g_13{left:71px;bottom:546px;letter-spacing:-0.09px;}
#t1h_13{left:78px;bottom:528px;}
#t1i_13{left:91px;bottom:528px;letter-spacing:-0.09px;}
#t1j_13{left:561px;bottom:535px;}
#t1k_13{left:46px;bottom:509px;letter-spacing:-0.1px;}
#t1l_13{left:54px;bottom:491px;}
#t1m_13{left:71px;bottom:491px;letter-spacing:-0.09px;}
#t1n_13{left:539px;bottom:498px;letter-spacing:-0.12px;}
#t1o_13{left:71px;bottom:473px;}
#t1p_13{left:84px;bottom:473px;letter-spacing:-0.09px;}
#t1q_13{left:91px;bottom:454px;letter-spacing:-0.1px;word-spacing:-0.01px;}
#t1r_13{left:105px;bottom:436px;letter-spacing:-0.27px;}
#t1s_13{left:71px;bottom:418px;}
#t1t_13{left:84px;bottom:418px;letter-spacing:-0.1px;}
#t1u_13{left:91px;bottom:399px;letter-spacing:-0.1px;word-spacing:-0.01px;}
#t1v_13{left:105px;bottom:381px;letter-spacing:-0.27px;}
#t1w_13{left:50px;bottom:344px;letter-spacing:-0.09px;}
#t1x_13{left:261px;bottom:344px;letter-spacing:-0.24px;word-spacing:-0.49px;}
#t1y_13{left:342px;bottom:344px;}
#t1z_13{left:50px;bottom:319px;letter-spacing:-0.1px;}
#t20_13{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_13{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_13{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_13{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_13{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_13{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_13{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_13{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_13{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_13{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_13{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_13{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_13{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_13{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_13{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_13{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sf_13{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts13" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg13Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg13" style="-webkit-user-select: none;"><object width="1210" height="935" data="13/13.svg" type="image/svg+xml" id="pdf13" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_13" class="t s0_13">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_13" class="t s1_13">® </span>
<span id="t3_13" class="t s0_13">(NCCN </span>
<span id="t4_13" class="t s1_13">® </span>
<span id="t5_13" class="t s0_13">), All rights reserved. NCCN Guidelines </span>
<span id="t6_13" class="t s1_13">® </span>
<span id="t7_13" class="t s0_13">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_13" class="t s2_13">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_13" class="t s2_13">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_13" class="t s3_13">NCCN Guidelines Version 4.2024 </span>
<span id="tb_13" class="t s3_13">Cancer of the Oral Cavity (Including Mucosal Lip) </span>
<span id="tc_13" class="t s4_13">NCCN Guidelines Index </span>
<span id="td_13" class="t s4_13">Table of Contents </span>
<span id="te_13" class="t s4_13">Discussion </span>
<span id="tf_13" class="t s5_13">OR-A </span>
<span id="tg_13" class="t s5_13">1 OF 2 </span>
<span id="th_13" class="t s6_13">1 </span>
<span id="ti_13" class="t s7_13">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_13" class="t s8_13">and </span><span id="tk_13" class="t s7_13">Discussion</span><span id="tl_13" class="t s8_13">. </span>
<span id="tm_13" class="t s6_13">2 </span>
<span id="tn_13" class="t s9_13">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An </span>
<span id="to_13" class="t s8_13">additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="tp_13" class="t s6_13">3 </span>
<span id="tq_13" class="t s8_13">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="tr_13" class="t s6_13">4 </span>
<span id="ts_13" class="t s8_13">Brachytherapy should be performed at centers where there is expertise in this modality. (Nag S, Cano ER, Demanes DJ, et al. The American Brachytherapy Society </span>
<span id="tt_13" class="t s9_13">recommendations for high-dose-rate brachytherapy for head-neck carcinomas. Int J Radiat Oncol Biol Phys 2001;50:1190-1198; and Mazeron JJ, Ardiet JM, Hale- </span>
<span id="tu_13" class="t s8_13">Meder C, et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009;91:150-156.) </span>
<span id="tv_13" class="t s6_13">5 </span>
<span id="tw_13" class="t s8_13">The interval between EBRT and brachytherapy should be as short as possible (1–2 weeks) depending on recovery from acute toxicity. The interval between HDR </span>
<span id="tx_13" class="t s8_13">fractions should be at least 6 hours. </span>
<span id="ty_13" class="t s5_13">PRINCIPLES OF RADIATION THERAPY </span>
<span id="tz_13" class="t sa_13">1 </span>
<span id="t10_13" class="t s5_13">DEFINITIVE: </span>
<span id="t11_13" class="t s5_13">RT Alone </span>
<span id="t12_13" class="t s5_13">• Planning target volume (PTV) </span>
<span id="t13_13" class="t sb_13"></span><span id="t14_13" class="t sc_13" data-mappings='[[94,"fi"]]'>High risk: Primary tumor and involved lymph nodes [this includes possible local subclinical inﬁltration at the primary site and at the high- </span>
<span id="t15_13" class="t s5_13">risk level lymph node(s)]: </span>
<span id="t16_13" class="t sd_13">◊ </span><span id="t17_13" class="t s5_13">Fractionation: </span>
<span id="t18_13" class="t s5_13">– 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </span>
<span id="t19_13" class="t sa_13">2 </span>
<span id="t1a_13" class="t s5_13">– Concomitant boost accelerated RT: </span>
<span id="t1b_13" class="t s5_13">– </span><span id="t1c_13" class="t sc_13" data-mappings='[[38,"fi"]]'>72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as second daily fraction during last 12 treatment days) </span>
<span id="t1d_13" class="t s5_13">– 66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1e_13" class="t s5_13">– Hyperfractionation: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily) </span>
<span id="t1f_13" class="t sb_13"></span><span id="t1g_13" class="t s5_13">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1h_13" class="t sd_13">◊ </span><span id="t1i_13" class="t s5_13">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1j_13" class="t sa_13">3 </span>
<span id="t1k_13" class="t s5_13">• Brachytherapy </span>
<span id="t1l_13" class="t sb_13"></span><span id="t1m_13" class="t s5_13">Interstitial brachytherapy is considered for selected cases. </span>
<span id="t1n_13" class="t sa_13">4,5 </span>
<span id="t1o_13" class="t sd_13">◊ </span><span id="t1p_13" class="t s5_13">Low dose-rate (LDR) brachytherapy (0.4–0.5 Gy/h): </span>
<span id="t1q_13" class="t s5_13">– Consider LDR boost 20–35 Gy if combined with 50 Gy external beam RT (EBRT) or 60–70 Gy over several days if using LDR as sole </span>
<span id="t1r_13" class="t s5_13">therapy. </span>
<span id="t1s_13" class="t sd_13">◊ </span><span id="t1t_13" class="t s5_13">High dose-rate (HDR) brachytherapy: </span>
<span id="t1u_13" class="t s5_13">– Consider HDR boost 21 Gy at 3 Gy/fraction if combined with 40–50 Gy EBRT or 45–60 Gy at 3–6 Gy/fraction if using HDR as sole </span>
<span id="t1v_13" class="t s5_13">therapy. </span>
<span id="t1w_13" class="t s5_13">For unresectable disease, </span><span id="t1x_13" class="t se_13">see ADV-1</span><span id="t1y_13" class="t s5_13">. </span>
<span id="t1z_13" class="t s5_13">Either intensity-modulated RT (IMRT) (preferred) or 3D conformal RT (3D-CRT) is recommended. </span>
<span id="t20_13" class="t sf_13">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
